https://www.selleckchem.com/pr....oducts/p5091-p005091
008). SRS-RARP was associated with decreased incontinence defined as 0-1 pad (HR 0.36, 95% CI 0.15-0.89, p=0.028), although not when defined as 0 pad (HR 0.56, 95% CI 0.31-1.01, p=0.053). On adjusted analysis SRS-RARP was associated with decreased pad per day. Lymph node dissection and primary treatment with SBRT were associated with longer console time. SRS-RARP is a feasible salvage option with significantly improved urinary function outcomes. This may warrant increased utilization of SRS-RARP to manage men who fail non-
Like
Comment
Share
